Europe has its first Lucentis biosimilar, Samsung Bioepis' B...

Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz.

Novartis says trials back Beovu safety in diabetic eye disea...

There is plenty of evidence that Novartis' ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whe

Roche eyes October decision by FDA for wet AMD implant

The FDA has started a review of a new implant version of Roche's ranibizumab therapy for wet age-related macular degeneration, that could offer patients with the sight-robbing disorder an a

Novartis taps smartpatient for app to support wet AMD patien...

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness.

Novartis’ blockbuster hope Beovu clears EMA advisory panel

MHRA says Avastin can be used for AMD despite Bayer, Novarti...